Medera
- Company typePrivate
- Founded2014
- HeadquartersBoston, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
Medera firmographics
Firmographics- Name
- Medera
- Legal name
- Medera Inc.
- Website
- https://medera.bio
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Medera industry classification
Industry- Product category
- Cardiovascular Gene Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI)
- akta.pro secondary industries
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ), Pulmonary Hypertension & Rare Pulmonary Disease Therapies (HLAIAIAG)
Keywords
Where Medera is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Medera business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Gene Therapy Development and Commercialization: As a clinical-stage biopharmaceutical company, Medera's primary revenue model is developing and commercializing gene therapy candidates. The company has three clinical-stage AAV-based cardiac gene therapy programs targeting heart failure and DMD-associated cardiomyopathy.
- Technology Platform Licensing and Services: Novoheart provides disease modeling and drug screening services to pharmaceutical companies using its human mini-Heart platform, including partnerships with AstraZeneca for CTScreen technology and disease model development.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Medera product offering
Product offeringCore offering
Medera is a clinical-stage biopharmaceutical company that develops gene- and cell-based therapeutic candidates for cardiovascular diseases through two wholly-owned divisions. Novoheart provides preclinical disease modeling and drug discovery services using a proprietary human mini-Heart platform of cardiac screening assays, while Sardocor advances clinical-stage AAV1/SERCA2a gene therapy candidates for heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), and Duchenne muscular dystrophy-associated cardiomyopathy (DMD-CM), administered via a proprietary minimally invasive intracoronary delivery methodology.
Product overview
Medera operates through two complementary business units: Novoheart and Sardocor. Novoheart provides the pre-clinical human mini-Heart platform (including Heart-in-a-Jar and CTScreen screening technology) for disease modeling and drug discovery. Sardocor leverages this platform to advance clinical-stage gene therapy candidates, including SRD-002 for HFpEF, SRD-001 for HFrEF, and AAV-SERCA2a for DMD-CM, all delivered via the company's proprietary intracoronary delivery methodology. The integrated approach spans from discovery through clinical development.
Differentiator
Problem solved
Functional benefit
Products and services
- SRD-002 (MUSIC-HFpEF) Investigational AAV1/SERCA2a gene therapy for heart failure with preserved ejection fraction (HFpEF), designed to restore cardiac calcium handling by increasing SERCA2a expression in cardiomyocytes, delivered via Medera's proprietary targeted intracoronary catheter-based outpatient procedure. Holds FDA Fast Track Designation.
- SRD-001 (MUSIC-HFrEF) Investigational AAV1/SERCA2a gene therapy for heart failure with reduced ejection fraction (HFrEF), currently in Phase 1b/2 clinical trial evaluating efficacy and safety in patients with NYHA class III/IV symptoms using Medera's targeted intracoronary delivery approach.
- AAV-SERCA2a (MUSIC-DMD) Investigational AAV1/SERCA2a gene therapy for cardiomyopathy secondary to Duchenne muscular dystrophy (DMD-CM), delivering the SERCA2a gene via AAV1 vector to restore calcium handling in cardiac muscle cells. Holds FDA Orphan Drug Designation and Fast Track Designation.
- Novoheart Preclinical Disease Modeling & Drug Discovery Service Pre-clinical disease modeling and drug discovery service offering using proprietary human mini-Heart platform (Heart-in-a-Jar) to generate human-specific preclinical drug safety, efficacy, and dosing data for pharmaceutical and biotech partners. Supports FDA Modernization Act 2.0 submissions.
- CTScreen v1.5 High-throughput automated cardiac screening platform supporting Novoheart's mini-Heart platform, accommodating up to 96 tissue samples in 96-well format for rapid screening with reduced cell requirements and costs. Licensed to pharmaceutical companies for automated cardiac drug screening.
Quantifiable outcome
- Up to 100x lower viral vector doses compared to conventional systemic IV methods
- +3 more outcomes
Companies that use Medera
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
Medera technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability3 records
Feature4 records
Medera partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and major.
- University of Kansas Medical CentercoreFirst patient treated in MUSIC-DMD Phase 1b clinical trial for DMD-associated cardiomyopathy gene therapy. Dr. Pradeep Mammen serves as principal investigator at the institution.
- Mayo Clinic and UC San Diego School of MedicinemajorCollaboration to develop first human mini-Heart models of hypoplastic left heart syndrome (HLHS) using patient stem cells. Mayo Clinic contributes biobank of 800+ HLHS patient samples; UC San Diego contributes clinical expertise with Dr. Paul Grossfeld leading pediatric cardiology.
- University Medical Center UtrechtmajorCTScreen installation at UMC Utrecht's Regenerative Medicine Center for human cardiac disease modeling and therapeutic screening. Partnership enables study of disease-specific mechanisms and drug safety using human-based assays.
- Curi BiocoreStrategic partnership integrating Novoheart's human Heart-in-a-Jar technology with Curi Bio's Pulse analytics platform for accelerated human-based cardiac drug development. Initial focus on adapting Pulse to process pressure-volume data from Heart-in-a-Jar.
- AstraZenecacoreAstraZeneca installed CTScreen v1.5 for advancing human heart-based R&D for investigational cardiovascular therapies. Multi-year collaboration including co-development of HFpEF disease model that contributed to FDA IND clearance and Fast Track Designation.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Medera competitors and assessment
Company assessmentDirect peers
- Rocket Pharmaceuticals: Clinical-stage AAV gene therapy company with a cardiac-focused program (RP-A601) for Danon disease cardiomyopathy. Directly comparable as a small-cap AAV gene therapy developer with a cardiac indication and similar regulatory designations (Orphan, Fast Track).
- Tenaya Therapeutics: Clinical-stage gene therapy company focused on heart failure and cardiomyopathies, with programs targeting both rare (genetic) and prevalent forms of heart disease using AAV-based approaches. Directly competes in the cardiac gene therapy space.
- Lexeo Therapeutics: Clinical-stage gene therapy company developing AAV-based cardiac therapeutics, including a SERCA2a program (LX2006) for Friedreich's ataxia cardiomyopathy and other cardiovascular gene therapies. Most directly comparable peer given overlapping cardiac AAV gene therapy approach and similar target indications.
Broad incumbents
- AskBio (Bayer): Large, established AAV gene therapy platform acquired by Bayer with deep cardiovascular and rare disease pipelines. Comparable as a broad incumbent in AAV gene therapy manufacturing and delivery, though larger and more diversified than Medera's focused cardiac pipeline.
- Sarepta Therapeutics: Commercial-stage gene therapy leader with Duchenne muscular dystrophy programs (Elevidys) and AAV manufacturing expertise. Overlaps with Medera on DMD-associated cardiomyopathy and AAV vector CMC, though broader in scope.
- Cytokinetics: Late-stage cardiovascular company developing cardiac myosin modulators for HFrEF and HFpEF (e.g., aficamten). Comparable as a competitor in the heart failure therapeutic space Medera is targeting with gene therapy.
- Bristol Myers Squibb: Large pharmaceutical company with significant cardiovascular franchise including heart failure drugs (e.g., acquired MyoKardia for cardiac genetic medicines). Competes broadly in heart failure therapeutics where Medera is developing its gene therapy pipeline.
- Novo Nordisk (Heart Failure Programs): Large pharmaceutical company with growing cardiovascular and heart failure franchises (e.g., semaglutide CV outcomes). Comparable as a large incumbent with deep pockets pursuing heart failure therapeutics where Medera is developing gene therapies.
Emerging players
- Insmed: Late-stage rare disease biopharmaceutical company with pulmonary programs (e.g., brensocatib for bronchiectasis) that overlap with Medera's preclinical pulmonary hypertension pipeline. Comparable for the rare-disease biopharma business model rather than direct therapeutic competition.
- Renovacor: Pre-clinical/early clinical gene therapy company that was developing AAV-based therapies for cardiomyopathy associated with BAG3 mutations (acquired by Lexeo Therapeutics in 2024). Comparable as a small-cap cardiac gene therapy player with similar modality.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks1 record
Key highlights7 records
Customer concentration
Medera social profiles
Digital presenceMedera compliance and trust
Trust signalCompliance4 records
Medera financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medera leadership team
Management profileNumber of profiles
Profiles12 records
Medera subsidiaries and ownership
Company hierarchySubsidiaries2 records
Medera funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medera M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medera
What does Medera do?
Medera is a clinical-stage biopharmaceutical company that develops gene- and cell-based therapeutic candidates for cardiovascular diseases through two wholly-owned divisions. Novoheart provides preclinical disease modeling and drug discovery services using a proprietary human mini-Heart platform of cardiac screening assays, while Sardocor advances clinical-stage AAV1/SERCA2a gene therapy candidates for heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), and Duchenne muscular dystrophy-associated cardiomyopathy (DMD-CM), administered via a proprietary minimally invasive intracoronary delivery methodology.
Is Medera a public or private company?
Medera is a private company. It is classified as venture growth investor backed and is currently operating.
When was Medera founded?
Medera was founded in 2014. It employs 51 to 100 people.
Where is Medera based?
Medera is headquartered in Boston, United States, in the North America region.
How does Medera make money?
Two revenue lines are on record. Gene Therapy Development and Commercialization is the primary driver. The others are technology Platform Licensing and Services.
Who are Medera's main competitors?
Direct peers on record are Rocket Pharmaceuticals, Tenaya Therapeutics and Lexeo Therapeutics. Broad incumbents are AskBio (Bayer), Sarepta Therapeutics, Cytokinetics, Bristol Myers Squibb and Novo Nordisk (Heart Failure Programs). Emerging players are Insmed and Renovacor.
Does Medera have an API?
No public API is recorded for Medera.
What industry is Medera in?
Medera's product category is Cardiovascular Gene Therapy. Its primary akta.pro industry code is HLAAACAI, Cardiometabolic & Other Systemic Gene Therapies, with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 325414 and its SIC code is 2834.